1. A retrospective analysis of patient-specific factors on voriconazole clearance. Issue 1 (December 2016) Authors: Dote, Satoshi; Sawai, Maki; Nozaki, Ayumu; Naruhashi, Kazumasa; Kobayashi, Yuka; Nakanishi, Hirokazu Journal: Journal of pharmaceutical health care and sciences Issue: Volume 2:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combination therapy of vancomycin and piperacillin/tazobactam in adult febrile neutropenia patients with haematopoietic malignancies increases the risk of acute kidney injury regardless of vancomycin trough concentration. (21st September 2021) Authors: Sazanami, Kohei; Inose, Ryo; Dote, Satoshi; Horiuchi, Nozomu; Kobayashi, Yuka; Muraki, Yuichi Journal: Journal of chemotherapy Issue: Volume 33:Number 6(2021) Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study. Issue 12 (15th October 2019) Authors: Dote, Satoshi; Ito, Kaori; Itakura, Shoji; Yasu, Takeo; Hira, Daiki; Noda, Satoshi; Yamada, Shigeki; Kobayashi, Yuka; Terada, Tomohiro Journal: Leukemia & lymphoma Issue: Volume 60:Issue 12(2019) Page Start: 2975 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Incidence of acute kidney injury after teicoplanin– or vancomycin– and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis. Issue 12 (December 2021) Authors: Sazanami, Kohei; Inose, Ryo; Yagi, Tatsuya; Dote, Satoshi; Horiuchi, Nozomu; Kobayashi, Yuka; Muraki, Yuichi Journal: Journal of infection and chemotherapy Issue: Volume 27:Issue 12(2021) Page Start: 1723 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗